MCM
TRIB

Marathon Capital Management’s Trinity Biotech TRIB Stock Holding History

Marathon Capital Management’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-148
Closed -$153K – 87
2016
Q4 		$153K Sell
148
-663
-82% -$685K 0.07% 73
2016
Q3 		$1.61M Buy
811
+88
+12% +$164K 0.8% 25
2016
Q2 		$1.23M Sell
723
-38
-5% -$64.3K 0.63% 27
2016
Q1 		$1.33M Buy
761
+154
+25% +$245K 0.69% 25
2015
Q4 		$1.07M Buy
+607
New +$1.07M 0.57% 31

Other funds holding TRIB

PIM
Paradice Investment Management Denver, Colorado $627M AUM 43.41% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $2.25B AUM 44.61% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
LAM
Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $486M AUM 50.29% 1-Year Est. Return
2L
22NW LP Seattle, Washington $105M AUM 38.33% 1-Year Est. Return
SCM
Stonehill Capital Management New York $350M AUM 73.6% 1-Year Est. Return
SM
Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return
HAIM
Hunter Associates Investment Management Pittsburgh, Pennsylvania $868M AUM 32.25% 1-Year Est. Return

Marathon Capital Management's TRIB Position: Q1 2017 in Review

Marathon Capital Management sold out of Trinity Biotech (TRIB) in Q1 2017, closing a stake of 148 shares — an estimated $153K sold.

Marathon Capital Management first reported a position in TRIB in Q4 2015 and held it in 5 quarters. The position peaked at $1.61M in Q3 2016. 67 funds tracked by Wall St. Rank hold TRIB as of Q1 2017.

  • Marathon Capital Management reported no remaining Trinity Biotech position as of Q1 2017 after selling out during the quarter.
  • Marathon Capital Management sold 148 Trinity Biotech shares in Q1 2017, an estimated $153K.
  • Marathon Capital Management first reported a position in Trinity Biotech in Q4 2015 and held it in 5 quarters.
  • Marathon Capital Management's Trinity Biotech position peaked at $1.61M in Q3 2016.
  • 67 funds tracked by Wall St. Rank held Trinity Biotech as of Q1 2017.

Based on Marathon Capital Management's 13F filing for Q1 2017, filed 4 May 2017.